| Phase 11 trial |
|
Phase 1
|
NCT06725381 |
Dec 2024 → Dec 2026 expected |
cancer |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 26 trials |
|
Phase 2
|
NCT07814066 |
Oct 2026 → Feb 2028 expected |
malignant pancreatic neoplasm |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07668154 |
Jul 2026 → Sep 2028 expected |
head and neck squamous cell carcinoma |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07622186 |
Jul 2026 → Dec 2028 expected |
non-small cell lung carcinoma |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07564466 |
Jun 2026 → Aug 2027 expected |
digestive system neoplasm |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07308106 |
Apr 2026 → Jun 2027 expected |
non-small cell lung carcinoma |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07230405 |
Jan 2026 → Jan 2028 expected |
non-small cell lung carcinoma |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|